Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Clover Health Investments Corp (NASDAQ: CLOV) was $3.98 for the day, up 6.42% from the previous closing price of $3.74. In other words, the price has increased by $6.42 from its previous closing price. On the day, 7.69 million shares were traded. CLOV stock price reached its highest trading level at $4.04 during the session, while it also had its lowest trading level at $3.7599.
Ratios:
Our analysis of CLOV’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 09 ’24 when Garipalli Vivek bought 531,700 shares for $1.88 per share. The transaction valued at 999,596 led to the insider holds 1,409,267 shares of the business.
Garipalli Vivek bought 877,567 shares of CLOV for $1,000,426 on Jun 17 ’24. The Director now owns 877,567 shares after completing the transaction at $1.14 per share. On May 16 ’24, another insider, Loengard Anna U, who serves as the Director of the company, bought 17,085 shares for $0.96 each. As a result, the insider paid 16,372 and bolstered with 15,600 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1994413824 and an Enterprise Value of 1661765248. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.30 while its Price-to-Book (P/B) ratio in mrq is 5.62. Its current Enterprise Value per Revenue stands at 0.786 whereas that against EBITDA is -21.558.
Stock Price History:
The Beta on a monthly basis for CLOV is 1.92, which has changed by 2.8241308 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.71, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is 16.63%, while the 200-Day Moving Average is calculated to be 71.60%.
Shares Statistics:
CLOV traded an average of 6.25M shares per day over the past three months and 6299230 shares per day over the past ten days. A total of 394.44M shares are outstanding, with a floating share count of 376.30M. Insiders hold about 24.91% of the company’s shares, while institutions hold 16.45% stake in the company. Shares short for CLOV as of 1735603200 were 15956062 with a Short Ratio of 2.55, compared to 1732838400 on 15276865. Therefore, it implies a Short% of Shares Outstanding of 15956062 and a Short% of Float of 3.9300002000000003.
